Highly-transmissible Variants of SARS-CoV-2 May Be More Susceptible to Drug Therapy Than Wild Type Strains
Verena Schöning, Charlotte Kern, Carlos Chaccour, Felix Hammann
doi:10.21203/rs.3.rs-379291/v1
As of March 2021, no antiviral drug regimen has proved effective against SARS-CoV-2 infection. With the pandemic showing no signs of slowing down, and vaccine campaigns only starting to be rolled out, we appear to have few options other than non-pharmacological measures. Emerging Variants of Concern (VOCs), e.g. B1.1.7, B.1.351, and B.1.1.248, however, are characterized by higher transmissibility (R0). Here we model and simulate the effect of altered R0 on viral load profiles, and its impact on antiviral therapy. As a hypothetical case study, we simulated treatment with ivermectin 600µg/kg for 3 days initiated at different time points around the infection. Simulated mutations range from 1.25 to 2-fold greater infectivity, but also include putative co-adapted variants with lower transmissibility (0.75-fold). Antiviral efficacy was correlated with R0, making highly transmissible VOCs more sensitive to antiviral therapy. Viral exposure was reduced by 42% compared to 22% in wild type if treatment was started on inoculation. Less transmissible variants appear less susceptible. Our findings suggest there may be a role for pre-or post-exposure prophylactic antiviral treatment in areas with presence of highly transmissible variants. Furthermore, clinical trials with borderline efficacious results should consider identifying VOCs and examine their impact in post-hoc analysis.
Author contributions VS: formal analysis, investigation, methodology, software, visualisation, writing -review & editing; CK: methodology, software, writing -review & editing; CC: validation, funding acquisition, writing -review & editing; FH: conceptualisation, formal analysis, funding acquisition, methodology, software, supervision, validation, visualisation, writing -original draft, writing -review & editing. All authors contributed to the final version.
Additional Information
Competing interests The author(s) declare no competing interests. above the serological positivity threshold (b). Black: wild type, blue: less transmissible, orange to red: highly transmissible.
Supplementary Files This is a list of supplementary les associated with this preprint. Click to download. 20210330Sars2variantssupplements.pdf
References
Chaccour, Hammann, Ramon-Garcia, Rabinovich, Ivermectin and COVID-19: Keeping Rigor in Times of Urgency, Am J Trop Med Hyg,
doi:10.4269/ajtmh.20-0271Chaccour, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebocontrolled, randomized clinical trial, EClinicalMedicine,
doi:10.1016/j.eclinm.2020.100720Cohen, South Africa suspends use of AstraZeneca's COVID-19 vaccine after it fails to clearly stop virus variant, Science
Duthaler, Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers, Br J Clin Pharmacol,
doi:10.1111/bcp.13840Faria, Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings
Goncalves, Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load, CPT Pharmacometrics Syst Pharmacol,
doi:10.1002/psp4.12543Kern, Schoening, Chaccour, Hammann, Modeling of SARS-CoV-2 treatment effects for informed drug repurposing, Front Pharmacol
Rambaut, Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
Schmith, Zhou, Lohmer, The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19, Clin Pharmacol Ther,
doi:10.1002/cpt.1889Siemieniuk, Drug treatments for covid-19: living systematic review and network meta-analysis, Bmj,
doi:10.1136/bmj.m2980Tegally, Emergence and rapid spread of a new severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa, medrXiv,
doi:10.1101/2020.12.21.20248640DOI record:
{
"DOI": "10.21203/rs.3.rs-379291/v1",
"URL": "http://dx.doi.org/10.21203/rs.3.rs-379291/v1",
"abstract": "<jats:title>Abstract</jats:title>\n <jats:p>As of March 2021, no antiviral drug regimen has proved effective against SARS-CoV-2 infection. With the pandemic showing no signs of slowing down, and vaccine campaigns only starting to be rolled out, we appear to have few options other than non-pharmacological measures. Emerging Variants of Concern (VOCs), e.g. B1.1.7, B.1.351, and B.1.1.248, however, are characterized by higher transmissibility (R0). Here we model and simulate the effect of altered R0 on viral load profiles, and its impact on antiviral therapy. As a hypothetical case study, we simulated treatment with ivermectin 600µg/kg for 3 days initiated at different time points around the infection. Simulated mutations range from 1.25 to 2-fold greater infectivity, but also include putative co-adapted variants with lower transmissibility (0.75-fold).Antiviral efficacy was correlated with R0, making highly transmissible VOCs more sensitive to antiviral therapy. Viral exposure was reduced by 42% compared to 22% in wild type if treatment was started on inoculation. Less transmissible variants appear less susceptible.Our findings suggest there may be a role for pre- or post-exposure prophylactic antiviral treatment in areas with presence of highly transmissible variants. Furthermore, clinical trials with borderline efficacious results should consider identifying VOCs and examine their impact in post-hoc analysis.</jats:p>",
"accepted": {
"date-parts": [
[
2021,
3,
31
]
]
},
"author": [
{
"affiliation": [
{
"name": "University of Bern"
}
],
"family": "Schöning",
"given": "Verena",
"sequence": "first"
},
{
"affiliation": [
{
"name": "University of Bern"
}
],
"family": "Kern",
"given": "Charlotte",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "ISGlobal, Hospital Clínic - Universitat de Barcelona"
}
],
"family": "Chaccour",
"given": "Carlos",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "University of Bern"
}
],
"family": "Hammann",
"given": "Felix",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
4,
15
]
],
"date-time": "2021-04-15T15:36:43Z",
"timestamp": 1618501003000
},
"deposited": {
"date-parts": [
[
2021,
4,
15
]
],
"date-time": "2021-04-15T15:36:43Z",
"timestamp": 1618501003000
},
"group-title": "In Review",
"indexed": {
"date-parts": [
[
2022,
4,
5
]
],
"date-time": "2022-04-05T06:23:00Z",
"timestamp": 1649139780925
},
"institution": [
{
"name": "Research Square"
}
],
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2021,
4,
15
]
]
},
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
4,
15
]
],
"date-time": "2021-04-15T00:00:00Z",
"timestamp": 1618444800000
}
}
],
"link": [
{
"URL": "https://www.researchsquare.com/article/rs-379291/v1",
"content-type": "text/html",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://www.researchsquare.com/article/rs-379291/v1.html",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "8761",
"original-title": [],
"posted": {
"date-parts": [
[
2021,
4,
15
]
]
},
"prefix": "10.21203",
"published": {
"date-parts": [
[
2021,
4,
15
]
]
},
"publisher": "Research Square Platform LLC",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.researchsquare.com/article/rs-379291/v1"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"subtype": "preprint",
"title": "Highly-transmissible Variants of SARS-CoV-2 May Be More Susceptible to Drug Therapy Than Wild Type Strains",
"type": "posted-content"
}
